person · Reporting owner
Audet Juliette Berangere
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | See Remarks | May 01, 2025 | May 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NewAmsterdam Pharma Co N.V.
Report date May 01, 2025 · Filed May 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.03 · Expires 2035-05-01 | Direct | 30,000 |
Reported balance
After 2025-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-01 · Grant · Acquired 30,000 · Balance 30,000 F1: 25% of the shares underlying the option will vest on May 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option will vest on May 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2025 Filed May 2, 2025 16:56 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $20.03 | $0.00 |
DisclosureSEC source: 0000950170-25-062897 · ownership.xml · derivative · entry 1 Audet Juliette Berangere · CIK 0002000393 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2035-05-01 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on May 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through such date. Read SEC document |
| January 07, 2025 Filed Jan 7, 2025 17:15 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 14,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002996 · ownership.xml · nonDerivative · entry 1 Audet Juliette Berangere · CIK 0002000393 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,104 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on January 7, 2025 for no consideration. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 17:54 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0000950170-25-002370 · ownership.xml · derivative · entry 1 Audet Juliette Berangere · CIK 0002000393 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through such date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 17:22 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | PurchaseOrdinary Shares | 1,104 | $15.70 | $17,332.80 |
DisclosureSEC source: 0000950170-24-110440 · ownership.xml · nonDerivative · entry 1 Audet Juliette Berangere · CIK 0002000393 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,104 Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 16:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 250,000 | $0.00 Strike: $21.37 | $0.00 |
DisclosureSEC source: 0000950170-24-040235 · ownership.xml · derivative · entry 1 Audet Juliette Berangere · CIK 0002000393 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Ordinary Shares · 250,000 shares Expires 2034-04-01 F1 · shares: The Reporting Person resigned from the Issuer's board of directors, effective April 1, 2024, in light of her appointment as the Issuer's Chief Business Officer ("CBO"). The option reported herein was granted in connection with the Reporting Person's appointment as CBO. F2 · derivative.exercise_date: 25% of the shares underlying the option will vest on April 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.